Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,929,659
  • Shares Outstanding, K 60,895
  • Annual Sales, $ 0 K
  • Annual Income, $ -103,690 K
  • EBIT $ -120 M
  • EBITDA $ -120 M
  • 60-Month Beta 0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.85

Options Overview Details

View History
  • Implied Volatility 92.68% (-1.15%)
  • Historical Volatility 77.33%
  • IV Percentile 25%
  • IV Rank 30.72%
  • IV High 238.27% on 01/07/26
  • IV Low 28.13% on 09/09/25
  • Expected Move (DTE 25) 2.72 (5.65%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 141
  • Volume Avg (30-Day) 713
  • Put/Call OI Ratio 1.57
  • Today's Open Interest 14,151
  • Open Int (30-Day) 6,715
  • Expected Range 45.39 to 50.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.44
  • Number of Estimates 1
  • High Estimate $-0.44
  • Low Estimate $-0.44
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) +22.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.70 +80.19%
on 03/18/26
48.53 -0.87%
on 04/17/26
+20.32 (+73.12%)
since 03/17/26
3-Month
24.90 +93.25%
on 01/29/26
48.53 -0.87%
on 04/17/26
+21.40 (+80.12%)
since 01/16/26
52-Week
14.78 +225.40%
on 01/06/26
48.53 -0.87%
on 04/17/26
+31.58 (+191.05%)
since 04/17/25

Most Recent Stories

More News
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

BOULDER, Colo. , Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 48.11 (+6.11%)
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts

ELVN : 48.11 (+6.11%)
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors

ELVN : 48.11 (+6.11%)
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small...

ELVN : 48.11 (+6.11%)
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer

ELVN : 48.11 (+6.11%)
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML

ELVN : 48.11 (+6.11%)
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery...

ELVN : 48.11 (+6.11%)
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and...

ELVN : 48.11 (+6.11%)
Next-Gen Cancer Treatments Gain Steam Amid Oncology Industry Shakeups

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer rates are climbing across the U.S., with stark disparities from state to state. Recent CDC data...

ONCY : 1.1200 (+5.66%)
INAB : 1.4400 (-0.69%)
ONC.TO : 1.42 (+2.16%)
TNGX : 26.64 (+6.39%)
MBIO : 0.7700 (+1.99%)
ELVN : 48.11 (+6.11%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 1.1200 (+5.66%)
BGNE : 184.71 (+0.49%)
HCM : 15.74 (+2.47%)
ABBV : 208.38 (-0.29%)
ONC.TO : 1.42 (+2.16%)
ELVN : 48.11 (+6.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO....

See More

Key Turning Points

3rd Resistance Point 52.26
2nd Resistance Point 50.39
1st Resistance Point 49.25
Last Price 48.11
1st Support Level 46.25
2nd Support Level 44.38
3rd Support Level 43.24

See More

52-Week High 48.53
Last Price 48.11
Fibonacci 61.8% 35.64
Fibonacci 50% 31.66
Fibonacci 38.2% 27.68
52-Week Low 14.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.